AAV8-3m vector system (Pancreas-validated AAV expression and packaging plasmid system)

GeneMedi’s AAV8 variant (Y733F,Y447F,Y275F) Vector System (AAV serotype 8 variant (Y733F,Y447F,Y275F) helper-free packaging plasmids system) is including AAV8 variant (Y733F,Y447F,Y275F) Rep-Cap plamid (AAV8 variant (Y733F,Y447F,Y275F) -RC plasmid), AAV helper plasmid and AAV expression vectors (overexpression or shRNA).

You can choose your suiltable AAV expression vector plasmids from GeneMedi’s AAV expression vector core. The AAV expression vector plasmids were constructed with differernt expression cassettes,containing kinds of verified protomters and reporters including GFP, zsgreen, RFP, mcherry and luciferase. The GeneMedi’s AAV expression vectors have been proved very suitalble for unique gene overexpression or shRNA-mediated knock-down (also called RNAi (RNA interference ). You can also achieve gene knock-out(KO) or gene editing using our Crispr-cas9-gRNA AAV expression vector.

AAV8 variant (Y733F,Y447F,Y275F) Rep-Cap plamid supplies the AAV8 Rep(replication) proteins and the AAV8 variant (Y733F,Y447F,Y275F) capsid-engineered protein.

The tissue tropism of AAV8 variant (Y733F, Y447F, Y275F) vector has been validated in in Pancreas, Pancreatic Tumors and retina,with potential applications in tissue-specific gene therapy and cancer therapy.

AAV8 capsid variant (Y733F,Y447F,Y275F) tissue tropism and gene transduction
(serotype-specific AAV infection)

The tissue tropism of AAV8 variant (Y733F, Y447F, Y275F) vector has been validated in in Pancreas, Pancreatic Tumors and retina,with potential applications in tissue-specific gene therapy and cancer therapy.

Virus and titer: AAV1/AAV6/AAV8/AAV-Rh10/AAV-DJ/AAV9-GFP, 1×10¹² vg/ml
Cells: HEK-293T
MOI: MOI=1×10⁴
Determine assay: 36 hours post infection, immunofluorescence microscopy